作为胺基酶1的标受hsa-let-7b-5p/LINC00665轴的调节,影响NSCLC的预后
Xu-Dong Zhu1, Yong-Fei Fan1, Yi Zhao1
1Department of Thoracic Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213003, China.
Heliyon
|November 13, 2023
概括
在非小细胞肺癌 (NSCLC) 中,高提米丁激酶1 (TK1) 表达与更差的预后相关. 该LINC00665/has-let-7b-5p/TK1网络可以作为NSCLC的预后生物标志物和治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 竞争性内源RNA (ceRNA) 网络与瘤生长有关,并代表潜在的治疗点.
- 提米丁激酶1 (TK1) 越来越多地被认为在癌症发展中的作用.
研究的目的:
- 研究TK1相关的ceRNA网络对非小细胞肺癌 (NSCLC) 预后的影响.
- 根据TK1表达及其调节网络,确定NSCLC潜在的预后生物标志物和治疗点.
主要方法:
- 从癌症基因组图谱 (TCGA) 获取了NSCLC和正常组织的TK1表达数据.
- 利用免疫组织化学和临床随访数据进行预后分析.
- 使用starBase数据库识别TK1向的microRNA和长非编码RNA来构建一个ceRNA网络.
主要成果:
- 与正常组织相比,在NSCLC组织中观察到显著更高的TK1表达.
- 提升的TK1表达与NSCLC患者的预后较差相关.
- 确定LINC00665/has-let-7b-5p/TK1网络是影响NSCLC生长和预后的关键调节器.
- TK1甲基化和免疫细胞透与NSCLC预后有关.
结论:
- 升高的TK1水平,可能由LINC00665/has-let-7b-5p/TK1网络介导,显著影响NSCLC的预后.
- TK1是NSCLC的潜在预后生物标志物和治疗点.
- 对TK1相关的ceRNA网络的进一步研究可能会导致NSCLC的新型治疗策略.
相关概念视频
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K